SEC Form 4 · accession 0000899243-18-001670
Corvus Pharmaceuticals, Inc. · CRVS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Joseph J Buggy
Officer — EVP Discovery Research
Period of report
Jan 19, 2018
Accepted (ET)
Jan 23, 2018 · 4:06 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001626971
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock, $0.0001 par valueF1 | holding | — | — | — | 84,876 | D | ||
| Common Stock, $0.0001 par valueF2 | holding | — | — | — | 266,310 | I | By Trust |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F3 | $9.94 | Jan 19, 2018 | A | 100,000 | A | — | Jan 19, 2028 | Common Stock | 100,000 | 100,000 | D |
Explanation of responses
- F1A portion of these shares is subject to a right of repurchase held by the Issuer.
- F2These shares are held by Buggy / Cooper Living Trust dated June 25, 2014, Joseph J. Buggy / Anne Cooper Trustees (the "Buggy Trust"). Dr. Buggy has shared voting, investment and dispositive power over the shares held by the Buggy Trust.
- F3The underlying shares subject to the option vest and become exercisable as to one-forty eighth (1/48th) of the shares subject to the option in successive, equal monthly installments measured from January 19, 2018, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date.